ArticleBMC gastroenterology2025
Preoperative serum prealbumin as a prognostic marker for survival after gallbladder cancer resection: a multicenter study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrealbumin, a marker of nutritional and inflammatory status, has shown prognostic value in various malignancies. This study aimed to evaluate the prognostic significance of preoperative serum prealbumin levels in gallbladder cancer (GBC) patients undergoing radical resection.
methodsA multicenter retrospective study included 210 patients who underwent radical GBC resection. The optimal prealbumin cutoff (221 mg/L) was identified via ROC analysis. Patients were stratified into high and low prealbumin groups. Kaplan-Meier and Cox regression analyses were used to assess the association between prealbumin levels and overall survival (OS) and recurrence-free survival (RFS).
resultsPatients with low prealbumin levels (n = 120) had 1-year OS and RFS rates of 65% and 44.1%, respectively. In contrast, high prealbumin patients (n = 90) showed significantly better OS (96.6%) and RFS (90%) (p < 0.001). Multivariate analysis confirmed prealbumin as an independent predictor of OS (HR = 0.179, 95% CI: 0.052-0.622, p = 0.007) and RFS (HR = 0.220, 95% CI: 0.102-0.474, p < 0.001). A combined model of prealbumin and hemoglobin improved predictive accuracy for OS (AUC = 0.762) and RFS (AUC = 0.771).
conclusionPreoperative serum prealbumin is an independent prognostic biomarker in GBC patients undergoing radical resection. Combining prealbumin with hemoglobin enhances prediction of postoperative survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.